JANE STREET GROUP, LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 115 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2021. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.

Quarter-by-quarter ownership
JANE STREET GROUP, LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$49,623
+50.3%
42,053
+79.6%
0.00%
Q2 2023$33,022
-96.3%
23,420
-96.1%
0.00%
Q1 2023$894,666
+441.4%
596,444
+322.3%
0.00%
Q4 2022$165,257
+334.9%
141,245
+315.2%
0.00%
Q3 2022$38,000
-59.1%
34,022
-42.3%
0.00%
Q2 2022$93,000
-51.3%
58,977
-52.5%
0.00%
Q1 2022$191,000
-74.9%
124,210
-60.1%
0.00%
Q4 2021$762,000
+382.3%
310,976
+397.2%
0.00%
Q3 2021$158,000
-75.7%
62,549
-72.6%
0.00%
Q2 2021$650,000
+291.6%
228,066
+223.3%
0.00%
Q1 2021$166,000
+207.4%
70,541
+129.7%
0.00%
Q4 2020$54,000
-68.6%
30,715
-83.3%
0.00%
Q3 2020$172,000
-80.2%
183,740
-81.6%
0.00%
-100.0%
Q2 2020$867,000
+452.2%
996,255
+424.5%
0.00%
Q1 2020$157,000
+265.1%
189,951
+291.9%
0.00%
Q4 2019$43,000
+65.4%
48,468
+85.2%
0.00%
Q3 2019$26,00026,1680.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2021
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$39,477,0003.01%
Raffles Associates 2,080,536$2,351,0002.51%
Defender Capital, LLC. 5,184,035$5,862,0002.30%
Prescott General Partners LLC 1,851,851$2,093,0000.16%
DAFNA Capital Management LLC 140,000$158,0000.04%
Fort Sheridan Advisors LLC 83,931$95,0000.03%
Long Focus Capital Management, LLC 215,000$243,0000.02%
XTX Topco Ltd 72,807$82,0000.02%
Ergoteles LLC 490,895$555,0000.02%
Beirne Wealth Consulting Services, LLC 45,000$51,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders